FDA clears Ventana's image analysis app for cancer detection

Ventana Medical Systems has been granted 510(k) clearance to go to market with an image analysis application used to detect breast and other types of cancer. The Ventana Companion HER2 (4B5) application assists pathologists with interpretation of images of a certain protein in tissue, according to a company statement.

Also receiving clearance was a Ventana application that allows digital reading of slides stained with the same protein. Both applications work with the company’s Virtuoso software and iScan Coreo Au scanner.

Oro Valley, Ariz.-based Ventana is owned by the Swiss pharmaceutical firm Roche.

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.